Alpha-1 antitrypsin (AAT) is a serum protease inhibitor that prevents lung injury from 24 protease production during cigarette smoking but causes severe liver disease once mutated. A 25 custom AAT antisense oligonucleotide (ASO) was found to be beneficial for the AATD liver 26 disease by blocking the mutated AAT transcripts. Here we hypothesized that knock-down of AAT 27 aggravates murine lung injury during smoke exposure and acute exacerbations of chronic 28 obstructive pulmonary disease (COPD). C57BL/6J mice were randomly divided into 4 groups for 29 each of the injury models, smoking (inhale for 3 months at 150mg/m 3 ) and smoke-flu (inhale for 30 2 weeks and intranasal influenza virus). The ASO and control (No-ASO) were injected 31 subcutaneously at 10ml/kg of body weight, starting with smoking or four days prior to influenza 32 infection weekly at 50mg/kg. ASO treatment during a 3 month smoke exposure significantly 33 increased the expression of Cela1 mRNA and decreased the serum and lung AAT expression. 34 However, despite the decrease in AAT, neither the inflammatory cell counts in the bronchoalveolar 35 lavage fluid (BALF) nor the lung structural changes were significantly affected by ASO treatment. 36 We observed significant differences in inflammation and emphysema due to smoke exposure alone. 37 With the smoke-flu model, similarly the major differences were found between smoke-flu and 38 room air control, with no additional effect with ASO treatment. Off-target effects or compensatory 39 mechanisms may account for this finding. Alternatively, the reduction of AAT with ASO treatment 40 was not robust enough to lead to lung injury. The result also suggest that the AAT ASO approach 41 for treating liver disease is relatively safe at the specified dose as it did not lead to detrimental 42 outcomes in the lung. These potential mechanisms need to be further investigated in order to fully 43 understand the impact of AAT inhibition on protease-antiprotease imbalance in the murine smoke 44 exposure model.
Introduction Alpha-1 antitrypsin (AAT) is a serum protease inhibitor that targets the proteases produced 48 during injury that, in the lung, are ultimately responsible for structural destruction. The protease-49 antiprotease paradigm has long been recognized and earlier research has identified neutrophil 50 elastase as one of the most potent proteases that mediates destruction in the lung [1, 2] . Alpha-1 51 antitrypsin inhibits neutrophil elastase activity [3] and prevents the degradation of elastin [4] , 52 which helps to maintain the integrity of extra-cellular matrix in the lung. Imbalances between 53 tissue damaging proteases and their inhibitors such as AAT leads to lung destruction and ultimately 54 the development of chronic obstructive pulmonary disease (COPD) [5] .
79 With the custom designed mouse AAT ASO, we can understand if AAT ASO inhibits the 80 expression of AAT in the lung similar to that in the liver. In addition, we can determine if AAT 81 modulation affects the outcome of smoking-induced lung injury and acute COPD exacerbation in 82 assessing the overall feasibility for using AAT ASO for treatment of liver disease in patients with 83 a pre-disposition to proteolytic lung destruction.
84

Materials and Methods
85
Alpha-1 Antitrypsin Antisense Oligonucleotide Treatment 86 Mouse AAT ASO and control ASO solution were prepared by Ionis Pharmaceutical in 87 collaboration with Keith Blomenkamp and Dr. Jeff Teckman in Saint Louis University with the 88 method described previously [11] . Two filter flasks were aliquoted upon arrival at 5mg/ml 89 concentration and administered via subcutaneous injection with a dose of 10ml/kg body weight 90 once a week, to make up a final weekly concentration of 50mg/kg.
91
Animal housing and smoke exposure
Western Blotting, ELISA, and qRT-PCR 143 The AAT protein expression in the lung was assessed with western blotting (alpha-1 144 antitrypsin antibody, #16382-1-AP, rabbit polyclonal, Proteintech, Rosemont, IL). Serum level of 145 AAT was evaluated with Mouse Alpha 1 Antitrypsin ELISA Kit (Product: ab205088, Let Number: 146 GR3272327). PCR probe for Cela1 (chymotrypsin-like elastase family, member 1) was purchased 147 from ThermoFisher (Applied Biosystems, Foster City, CA; Assay ID: Mm00712898_m1; Cat 148 #4331182). Cela1 was implicated with mouse lung development and human AATD [12, 20] . 150 Simple pairwise comparisons were performed with Students t-test or Wilcoxon-test (non-151 parametric test for the survival curve) assuming unequal variance. Additional tests were performed 152 after grouping both ASO control and treated mice, for example, overall flu (FN&FA) vs control 153 (AN&AA), when ASO treatment did not make any significant difference. All error bars indicate 154 mean ± SEM. 158 Endogenous AAT protein expression in the serum (Figure 2A , P<0.005; N=8~10) and the 159 lung ( Figure 2B , P<0.001; N=6, from 3 western blots, Figure S2 ) and were significantly reduced 160 in mice injected with ASO. The injection also significantly increased the Cela1 expression for the 161 air-exposed mice (AA vs AN, P=0.004) but not for the smoke-exposed mice (SA vs SN, P=0.8; 162 Figure 2C ).
149
Statistical analysis
155
Results
156
ASO treatment effectively knocked down the AAT protein 157 expression and induced the expression of Cela1 in the lung
163
ASO did not significantly modulate lung responses of mice in a
164 smoke-induced lung injury model 165 Lung function testing results measured by flexiVent showed an overall significantly 166 increased inspiratory capacity for mice exposed to smoke (SN&SA vs AN&AA, P=0.01, Figure  167 3A ). ASO treatment did not contribute to any changes in inspiratory capacity, resistance, or 168 compliance regardless of the exposure conditions ( Figure 3B ).
Despite the significantly increased inflammatory cells in the bronchoalveolar lavage fluid 170 (BALF) of the smoke-exposed mice (SN vs AN, P=0.04), the BALF inflammatory cell counts 171 were not significantly affected by ASO treatment (P>0.19; Figure 3C ). Analysis of the lung 172 morphometry in the mice demonstrated emphysema development with smoke exposure alone 173 (Mean Linear Intercept, P=0.02; Ductal/destructive Size, P=0.008), which was not further 174 aggravated by the reduction of AAT with the ASO (P>0.05). Although the ASO treatment 175 successfully decreased the expression of AAT in the serum and the lung, no additive effect was 176 seen when these mice were exposed to smoke ( Figure 3A~3F ).
177
ASO did not significantly affect survival and lung responses of 178 mice exposed to smoke and influenza infection 179 Both groups exposed to smoke and influenza virus exhibited mortality of ~50% two weeks 180 after the infection ( Figure 4A ), which was also accompanied by significant weight loss. The most 181 weight loss (26.49%) was observed at day 12 post infection followed by weight gain until sacrifice 182 date ( Figure 4B ).
183
Similar to smoke exposure alone, there was significantly increased inflammation due to 184 smoke exposure and flu infection (FN vs AN, P=0.018 ). However, the ASO treatment did not 185 contribute to any significant changes (P>0.1). Between all smoke-flu exposed and air exposed 186 mice, there are significant differences at day #17 and #18 after first dose of antisense 187 oligonucleotide for the survival rate and between day #7 and day #18 for the body weight.
188
Discussion
189
Consistent with the previous study, where an 80% reduction in circulating AAT was found 190 in the liver after AAT ASO treatment, we also found more than 50% reduction in AAT protein 191 expression in the serum and the lung (Figure 2A-B) . As one of the digestive enzymes that can be 192 covalently neutralized by AAT and played an important role in emphysema development, we first 193 examined the expression of chymotrypsin-like elastase 1 (Cela1) [20] . Although ASO did not 194 further increase the expression of Cela1 for the mice exposed to cigarette smoke, it did bring up 195 Cela1 expression of air-exposed mice to a comparable level to those exposed to smoke. This 196 suggests that the smoke exposure by itself may have already maximized Cela1 expression. 197 Therefore, down-regulating protease inhibitor would not favor further over-expression of Cela 198 ( Figure 2C) . From another perspective, the AAT expression is still present at a detectable level 199 (Figure 2A-B) . This level of AAT may remain effective and functional, especially in comparison
Figure Legends
317 Figure 1 . Experimental design. Alpha-1 antitrypsin antisense oligonucleotide treatment 318 was tested on two sets of lung injury models, smoke exposure for chronic obstructive pulmonary 319 disease (COPD) and additional flu infection for COPD exacerbation. Each experiment was 320 randomly divided into 4 groups, first letter indicating the lung injury model, second letter whether 321 treated with ASO.
322
Figure 2. Alpha-1 antitrypsin (AAT) expression was significantly decreased by the 323 antisense oligonucleotide treatment. Although the treatment lead to decreased AAT in the serum 324 (A; P<0.005) and the lung (B; P<0.001) and increased Cela1 elastase expression (C; P=0.014), 325 Cela1 was highly expressed in smoke exposed mice and did not increase further by oligonucleotide 326 treatment (P=0.80). 
